GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (XTAE:RDHL) » Definitions » Net Change in Cash

Redhill Biopharma (XTAE:RDHL) Net Change in Cash : ₪-74.5 Mil (TTM As of Jun. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Redhill Biopharma Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Redhill Biopharma's Net Change in Cash for the three months ended in Jun. 2023 was ₪-39.4 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 was ₪-74.5 Mil.

Redhill Biopharma Net Change in Cash Historical Data

The historical data trend for Redhill Biopharma's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Net Change in Cash Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 1.01 0.67 -35.44 -53.68

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.93 17.76 -8.94 -39.42 -

Redhill Biopharma Net Change in Cash Calculation

Redhill Biopharma's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-133.526+0.015+79.918+-0.082
=-53.7

Redhill Biopharma's Net Change in Cash for the quarter that ended in Jun. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-39.473+-0.026+0.011+0.067
=-39.4

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-74.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Redhill Biopharma Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma (XTAE:RDHL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (XTAE:RDHL) » Definitions » Net Change in Cash
Comparable Companies
CLSH PLSH CNNC YCBD PTPI HENC KOAN STEK CLVR JUVAF ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
RDHL:USA 2RH0:Germany 2RH0:Germany
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Website
https://www.redhillbio.com
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.